There was certainly no traditional Summer lull this year for Consilium Strategic Communications. Our clients continued to communicate on their progress and key business developments apace throughout the Summer months, despite COVID-19.
We were pleased to re-open our office on 3rd August and have some resemblance of normality in seeing colleagues and clients in the City and at their HQs again. Safety remains of paramount importance to Consilium and we remain ever grateful for our good health and the dedication of our colleagues who have worked tirelessly from home since April.
Journalists have begun coming up for air following the COVID-19 reporting frenzy and we are pleased to be seeing them conduct media interviews across the sector. While we are delighted about this, our current view is that investors and analysts are still preferring to conduct meetings virtually and this continues to be refreshingly efficient with regard to management’s time. Bankers are enjoying being back in their offices and capital markets/M&A within our sector is certainly buoyant.
We feel lucky to be working in the healthcare sector and continue to enjoy supporting our strong portfolio of international clients and to be back working in the office together and getting to know new members of the team.
Consilium was pleased to hire Ashley Tapp as a Senior Associate Partner and Kris Lam as an Account Executive, during lock-down and Sue Charles joined us as a Senior Strategic Advisor. We also promoted Chris Welsh to Senior Associate Partner – congratulations Chris!
As usual, we will be hosting our annual conference, albeit virtually, this year on Monday 16th November 2020 from 2-4pm GMT, ahead of the annual Jefferies European Healthcare conference.
This year’s agenda will involve two main sessions, a fireside chat, for which we have Jan van de Winkel, President and Chief Executive Officer of Genmab, talking to Clive Cookson, Science Editor at the Financial Times, and a panel discussion: The Impact of COVID-19 on the future of healthcare. Panellists include George Goldsmith, Chairman, Chief Executive Officer and Co-founder, Compass Pathways. Linden Thomson, Lead Manager, AXA Framlington Biotech Fund. Martin Murphy, Chief Executive Officer, Syncona. Professor Tom Wilkinson, Professor of Respiratory Medicine University of Southampton, Co-Founder, my mHealth; Trial Chief Investigator of Synairgen’s SNG001.
It’s free to attend and please click here to register.
We look forward to seeing our clients and contacts socially distanced in person soon and in the meantime wish everyone well in these unprecedented times.
